Innocare 诺诚健华
19 significant filings since 29 May 2026: 15 on equity incentive, 2 on major holder selling and 1 on major contract or bid won, and 1 other kind. The latest, on 24 Sep 2026: 诺诚健华医药有限公司关于子公司与礼来公司签署研发合作及授权许可协议的公告.
自 29 May 2026 起有 19 份重大公告：equity incentive 15 份、major holder selling 2 份、major contract or bid won 1 份，另有 1 类。最新一份（24 Sep 2026）：诺诚健华医药有限公司关于子公司与礼来公司签署研发合作及授权许可协议的公告。
Price History 价格走势
5 sessions 个交易日, 18 Sep to 24 Sep 2026 · Live one-minute prices · High 最高 ¥34.00 · Low 最低 ¥28.14 · −10.60% on the previous close of ¥33.40The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 27 Aug 2025 | 浦银国际证券 | 阳景,胡泽宇 | Neutral 中性 | ▲ | Buy 买入 |
| 13 Nov 2024 | 浦银国际证券 | 阳景,胡泽宇 | Buy 买入 | ▼ | Neutral 中性 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 国信证券 | 陈曦炳,彭思宇,陈益凌,肖婧舒 | Outperform 增持 | 23 Sep 2026 | 1 | 38.36 |
| 长城国瑞证券 | 胡晨曦 | Buy 买入 | 31 Aug 2026 | 2 | — |
| 国金证券 | 甘坛焕,刘创 | Buy 买入 | 26 Aug 2026 | 2 | — |
| 开源证券 | 余汝意,聂媛媛 | Buy 买入 | 26 Aug 2026 | 2 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 1 of 7 reports. 每行为该券商近十二个月的最新研报；7 份中 1 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。